- Home
- RGF vs BCDA Comparison
RGF vs BCDA Comparison
Compare RGF & BCDA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RGF
- BCDA
- Stock Information
- Founded
- RGF 2016
- BCDA N/A
- Country
- RGF United States
- BCDA United States
- Employees
- RGF N/A
- BCDA N/A
- Industry
- RGF Packaged Foods
- BCDA Biotechnology: Pharmaceutical Preparations
- Sector
- RGF Consumer Staples
- BCDA Health Care
- Exchange
- RGF Nasdaq
- BCDA Nasdaq
- Market Cap
- RGF 8.3M
- BCDA 7.9M
- IPO Year
- RGF 2021
- BCDA N/A
- Fundamental
- Price
- RGF $0.36
- BCDA $2.60
- Analyst Decision
- RGF Hold
- BCDA Strong Buy
- Analyst Count
- RGF 1
- BCDA 1
- Target Price
- RGF $0.50
- BCDA $25.00
- AVG Volume (30 Days)
- RGF 1.2M
- BCDA 74.1K
- Earning Date
- RGF 11-08-2024
- BCDA 11-06-2024
- Dividend Yield
- RGF N/A
- BCDA N/A
- EPS Growth
- RGF N/A
- BCDA N/A
- EPS
- RGF N/A
- BCDA N/A
- Revenue
- RGF $156,379,000.00
- BCDA $428,000.00
- Revenue This Year
- RGF $23.67
- BCDA $6.92
- Revenue Next Year
- RGF N/A
- BCDA N/A
- P/E Ratio
- RGF N/A
- BCDA N/A
- Revenue Growth
- RGF 18.88
- BCDA 0.71
- 52 Week Low
- RGF $0.21
- BCDA $1.96
- 52 Week High
- RGF $2.75
- BCDA $23.25
- Technical
- Relative Strength Index (RSI)
- RGF 45.74
- BCDA 46.60
- Support Level
- RGF $0.33
- BCDA $2.39
- Resistance Level
- RGF $0.40
- BCDA $2.84
- Average True Range (ATR)
- RGF 0.04
- BCDA 0.17
- MACD
- RGF 0.00
- BCDA -0.00
- Stochastic Oscillator
- RGF 56.82
- BCDA 41.18
About RGF The Real Good Food Company Inc.
The Real Good Food Company Inc is an high-growth, branded, health- and wellness-focused frozen food company. It develops, markets, and manufactures delicious and convenient comfort foods designed to be high in protein, low in sugar, and made from gluten- and grain-free ingredients that are intended to be sold in the health and wellness segment of the frozen food category. All of its revenue is derived from the United States.
About BCDA BioCardia Inc.
BioCardia Inc is a clinical-stage company developing cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary diseases with significant unmet medical needs. Its two cell therapy platforms derived from the bone marrow. CardiAMP autologous mononuclear cell therapy platform is being advanced for two clinical indications: ischemic heart failure with reduced ejection fraction (HFrEF) and refractory angina resulting from chronic myocardial ischemia (CMI). Its immunomodulatory allogeneic mesenchymal stem cell (MSC) therapy platform is being an "off the shelf" cell therapy for two clinical indications: the treatment of ischemic HFrEF (CardiALLO), which is actively enrolling, and acute respiratory distress syndrome (ARDS).